JPRN-jRCT2080223428已完成1 期
A Phase 1 Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Must have histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable)
- •Must have received, and then progressed or been intolerant to, standard treatment regimen in the advanced or metastatic setting, if such a therapy exists
- •Presence of at least one lesion with measurable disease as defined by RECIST v1.1 criteria for response assessment
排除标准
- •Known or suspected CNS (central nervous system) metastases or with the CNS as the only site of active disease
- •Other concomitant malignancies (with some exceptions per protocol)
- •Any active autoimmune disease or history of known or suspected autoimmune disease
- •History of uncontrolled or significant cardiovascular disease
研究者
相似试验
已完成
不适用
A phase I study of the safety, tolerability, and antitumor activity of escalating doses of combretastatin A4 phosphate given in combination with bevacizumab to subjects with advanced solid tumorsAdvanced solid tumoursSolid tumoursCancerISRCTN96787846OXiGENE, Inc. (USA)12
终止
1 期
A Phase I/II Study of the Tolerability, Safety and Pharmacokinetics of Oral Monepantel (MPL) in Individuals with Treatment-Refractory Solid Tumours.Cancer - Any cancerCancerACTRN12614000612617PharmAust Limited9
已完成
1 期
A Phase I Study of SCC244 in Japanese Patients with Advanced Solid TumorsSolid tumorsJPRN-jRCT2080225124Shanghai Haihe Pharmaceutical Co., Ltd.6
尚未招募
1 期
Study to evaluate safety of LNP8701 in patients with different types of Metastatic solid cancersCTRI/2024/08/072373upin Limited
已完成
1 期
An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid TumorsJPRN-jRCT2080224176Bristol-Myers Squibb K.K.6